EGFR and non-small cell lung carcinoma: Indeed, growing evidence suggests that dynamic evaluation of miRNA levels, detected in patients’ plasma samples, could represent an emerging useful tool for the monitoring of EGFR-TKI therapy in EGFR-driven NSCLC, but this approach has not yet been implemented in the clinical practice [9].